Schlienger Nathalie, Lund Birgitte W, Pawlas Jan, Badalassi Fabrizio, Bertozzi Fabio, Lewinsky Rasmus, Fejzic Alma, Thygesen Mikkel B, Tabatabaei Ali, Bradley Stefania Risso, Gardell Luis R, Piu Fabrice, Olsson Roger
ACADIA Pharmaceuticals AB, Medeon Science Park, S-205 12 Malmo, Sweden.
J Med Chem. 2009 Nov 26;52(22):7186-91. doi: 10.1021/jm901149c.
Herein we describe the discovery of ACP-105 (1), a novel and potent nonsteroidal selective androgen receptor modulator (SARM) with partial agonist activity relative to the natural androgen testosterone. Compound 1 was developed from a series of compounds found in a HTS screen using the receptor selection and amplification technology (R-SAT). In vivo, 1 improved anabolic parameters in a 2-week chronic study in castrated male rats. In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.
在此,我们描述了ACP-105(1)的发现,它是一种新型且强效的非甾体选择性雄激素受体调节剂(SARM),相对于天然雄激素睾酮具有部分激动剂活性。化合物1是从使用受体选择和扩增技术(R-SAT)的高通量筛选中发现的一系列化合物中开发而来的。在体内,在去势雄性大鼠的为期2周的慢性研究中,1改善了合成代谢参数。除了化合物1之外,还从同一系列化合物中发现了许多强效抗雄激素,其中一种化合物13对参与前列腺癌的AR T877A突变体具有拮抗活性。